Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two main segments: Diagnostic Substances and Therapeutic Development Programs, leveraging its proprietary Manocept platform to target the CD206 mannose receptor on activated macrophages. This technology supports various diagnostic modalities, such as single photon emission computed tomography, positron emission tomography, gamma-scanning, and optical-fluorescence detection, while also enabling delivery of therapeutic compounds for immune- and inflammation-related diseases. The company advances products like NAV3-31, NAV3-35, NAV3-33, and NAV3-32, primarily for rheumatoid arthritis imaging and treatment monitoring, alongside applications in cancer, cardiovascular conditions, Kaposi’s sarcoma, and tuberculosis. Founded in 1983 and headquartered in Columbus, Ohio, Navidea Biopharmaceuticals, Inc. plays a role in the biotechnology sector by pursuing innovations in precision medicine to enhance diagnostic accuracy and targeted therapies for inflammatory and autoimmune disorders.